Extending patient survival with next-generation treatment combinations.

Development Pipeline

We are advancing a pipeline of innovative immuno-oncology programs.

Coherus Oncology is developing a diversified pipeline of immuno-oncology therapeutics that can be part of next-generation treatment combinations to extend survival for patients with cancer across difficult-to-treat tumor types. Our pipeline programs have distinct targets designed to inhibit immune suppressive mechanisms in the tumor microenvironment with the goal of delivering powerful anti-tumor activity and, ultimately, transforming outcomes for patients. Our pipeline includes a range of novel preclinical and clinical-stage immuno-oncology programs currently in development.

Coherus-led Immuno-oncology Programs
Program
Description
Indication
Stage
  • Preclinical
  • Phase 1
  • Phase 2
  • Pivotal
  • Approved
LOQTORZI®
(toripalimab-tpzi)*
Anti-PD-1 monoclonal antibody
1L Nasopharyngeal Carcinoma

(combo with chemotherapy)
Approved
2L+ Nasopharyngeal Carcinoma

(monotherapy)
Approved
Approved
Approved
Tagmokitug**
Anti-CCR8 monoclonal antibody
4L+ Colorectal Cancer
(combo with toripalimab)
Phase 2
2L HNSCC
(combo with toripalimab)
Phase 1
2L Gastric Cancer
(combo with toripalimab)
Phase 1
1L/2L Esophageal Cancer
(combo with toripalimab)
Phase 1
3L+ mCRPC
(combo with pasritamig-J&J)
Pre Clin.
Phase 2
Phase 1
Phase 1
Phase 1
Pre Clin.
Casdozokitug**
IL-27 antagonist monoclonal antibody
1L Hepatocellular Carcinoma
(combo with toripalimab + bevacizumab)
Phase 2
Phase 2

* Coherus Oncology owns all rights to LOQTORZI® in the United States, and has licensed to Apotex, Inc. the right solely to commercialize and sell LOQTORZI in Canada.
** Coherus Oncology owns worldwide right for casdozokitug and tagmokitug.

Learn more about toripalimab, our next generation anti-PD-1 monoclonal antibody.

See Toripalimab – PD-1 Inhibitor